MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine) Disease Interactions
There are 3 disease interactions with MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine):
Vaccines (Includes MenHibrix) ↔ IM injection
Severe Potential Hazard, Moderate plausibility. Applies to: Thrombocytopenia, Thrombocytopathy, Coagulation Defect, Thrombocytopenia, Thrombocytopathy, Coagulation Defect
In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
- "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
- American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
- "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
Meningococcal conjugate vaccine (Includes MenHibrix) ↔ GBS
Moderate Potential Hazard, Moderate plausibility. Applies to: Guillain-Barre Syndrome
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.
Vaccines (live attenuated/toxoid) (Includes MenHibrix) ↔ immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applies to: Immunodeficiency, Immunodeficiency
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine) drug interactions
There are 202 drug interactions with MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine)
More about MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine)
- MenHibrix Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Drug class: bacterial vaccines
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.